SS Innovations Reports Second Quarter 2025 Financial Results
SS Innovations (NASDAQ:SSII) reported strong Q2 2025 financial results, with record quarterly revenue of $10.0 million, up 121.8% year-over-year. The company's gross margin expanded significantly to 59.1% from 31.9% in Q2 2024, while gross profit surged 311.4% to $5.9 million.
The SSi Mantra surgical robotic system achieved 23 new installations in Q2, a 130% increase from the previous year, bringing the total installed base to 105 systems across seven countries. The company reported 4,657 cumulative surgeries and expects to submit a 510(k) application to the FDA by September 2025. Notable achievements include the world's first robotic cardiac surgery in the Western Hemisphere and breakthrough telesurgery procedures.
The company maintains a strong financial position with zero long-term debt and $11.4 million in cash. SS Innovations successfully uplisted to Nasdaq in April 2025, marking a new phase in its global expansion strategy.
SS Innovations (NASDAQ:SSII) ha riportato risultati finanziari solidi per il secondo trimestre del 2025, con un fatturato trimestrale record di 10,0 milioni di dollari, in crescita del 121,8% rispetto all'anno precedente. Il margine lordo dell'azienda 猫 aumentato significativamente, passando dal 31,9% al 59,1% nel Q2 2024, mentre il profitto lordo 猫 cresciuto del 311,4%, raggiungendo 5,9 milioni di dollari.
Il sistema chirurgico robotico SSi Mantra ha registrato 23 nuove installazioni nel secondo trimestre, un aumento del 130% rispetto all'anno precedente, portando il totale degli impianti a 105 sistemi distribuiti in sette paesi. L'azienda ha riportato 4.657 interventi chirurgici cumulativi e prevede di presentare una domanda 510(k) alla FDA entro settembre 2025. Tra i risultati pi霉 rilevanti si annoverano il primo intervento chirurgico cardiaco robotico nel continente americano e procedure di telesurgia all'avanguardia.
L'azienda mantiene una solida posizione finanziaria con zero debiti a lungo termine e 11,4 milioni di dollari in contanti. SS Innovations 猫 stata quotata con successo al Nasdaq nell'aprile 2025, segnando una nuova fase nella sua strategia di espansione globale.
SS Innovations (NASDAQ:SSII) report贸 s贸lidos resultados financieros en el segundo trimestre de 2025, con un ingreso trimestral r茅cord de 10.0 millones de d贸lares, un aumento del 121.8% respecto al a帽o anterior. El margen bruto de la empresa se expandi贸 significativamente, pasando del 31.9% al 59.1% en el segundo trimestre de 2024, mientras que la ganancia bruta se dispar贸 un 311.4%, alcanzando los 5.9 millones de d贸lares.
El sistema quir煤rgico rob贸tico SSi Mantra logr贸 23 nuevas instalaciones en el segundo trimestre, un incremento del 130% respecto al a帽o anterior, llevando la base total instalada a 105 sistemas en siete pa铆ses. La compa帽铆a report贸 4,657 cirug铆as acumuladas y espera presentar una solicitud 510(k) a la FDA para septiembre de 2025. Entre los logros destacados se encuentran la primera cirug铆a card铆aca rob贸tica en el hemisferio occidental y procedimientos innovadores de telescirug铆a.
La empresa mantiene una posici贸n financiera s贸lida con cero deuda a largo plazo y 11.4 millones de d贸lares en efectivo. SS Innovations logr贸 su uplisting al Nasdaq en abril de 2025, marcando una nueva etapa en su estrategia de expansi贸n global.
SS Innovations (NASDAQ:SSII)電� 2025雲� 2攵勱赴 臧曤牓頃� 鞁れ爜鞚� 氚滍憸頃橂┌, 攵勱赴 毵れ稖鞎� 1,000毵� 雼煬搿� 靷儊 斓滉碃旃橂ゼ 旮半頃橃棳 鞝勲厔 霃欔赴 雽�牍� 121.8% 歃濌皜頄堨姷雼堧嫟. 須岇偓鞚� 齑濎澊鞚惦鞚� 2024雲� 2攵勱赴 31.9%鞐愳劀 59.1%搿� 韥矊 頇曤寑霅橃棃鞙茧┌, 齑濎澊鞚奠潃 311.4% 靸侅姽頃� 590毵� 雼煬毳� 旮半頄堨姷雼堧嫟.
SSi Mantra 靾橃垹鞖� 搿滊磭 鞁滌姢韰滌潃 2攵勱赴鞐� 23雽�鞚� 鞁犼窚 靹れ箻毳� 雼劚頃� 鞝勲厔 雽�牍� 130% 歃濌皜頄堨溂氅�, 齑� 靹れ箻 雽�靾橂姅 7臧滉淡鞐愳劀 105雽�鞐� 鞚措雼堧嫟. 雸勳爜 靾橃垹 瓯挫垬電� 4,657瓯�鞚措┌, 2025雲� 9鞗旉箤歆� FDA鞐� 510(k) 鞁犾箔靹滊ゼ 鞝滌稖頃� 鞓堨爼鞛呺媹雼�. 欤检殧 靹标臣搿滊姅 靹滊皹甑� 斓滌磮鞚� 搿滊磭 鞁灔 靾橃垹瓿� 順侅嫚鞝侅澑 鞗愱博 靾橃垹 鞝堨皑臧� 韽暔霅╇媹雼�.
须岇偓电� 鞛リ赴 攵�毂� 鞐嗢澊 1,140毵� 雼煬鞚� 順勱笀 氤挫湢搿� 韮勴儎頃� 鞛 靸來儨毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟. SS Innovations電� 2025雲� 4鞗� 雮橃姢雼� 靸侅灔鞚� 靹标车鞝侅溂搿� 鞕勲頃橂┌ 旮�搿滊矊 頇曥灔 鞝勲灥鞚� 靸堧鞖� 雼硠毳� 毵烄澊頄堨姷雼堧嫟.
SS Innovations (NASDAQ:SSII) a annonc茅 de solides r茅sultats financiers pour le deuxi猫me trimestre 2025, avec un chiffre d'affaires trimestriel record de 10,0 millions de dollars, en hausse de 121,8 % par rapport 脿 l'ann茅e pr茅c茅dente. La marge brute de l'entreprise s'est nettement am茅lior茅e, passant de 31,9 % 脿 59,1 % au deuxi猫me trimestre 2024, tandis que le b茅n茅fice brut a bondi de 311,4 % pour atteindre 5,9 millions de dollars.
Le syst猫me chirurgical robotis茅 SSi Mantra a enregistr茅 23 nouvelles installations au deuxi猫me trimestre, soit une augmentation de 130 % par rapport 脿 l'ann茅e pr茅c茅dente, portant le parc total install茅 脿 105 syst猫mes dans sept pays. L'entreprise a rapport茅 4 657 interventions cumul茅es et pr茅voit de soumettre une demande 510(k) 脿 la FDA d'ici septembre 2025. Parmi les r茅alisations notables figurent la premi猫re chirurgie cardiaque robotis茅e en Am茅rique occidentale et des proc茅dures r茅volutionnaires de t茅l茅chirurgie.
L'entreprise maintient une solide position financi猫re avec aucune dette 脿 long terme et 11,4 millions de dollars en liquidit茅s. SS Innovations a r茅ussi son introduction au Nasdaq en avril 2025, marquant une nouvelle 茅tape dans sa strat茅gie d'expansion mondiale.
SS Innovations (NASDAQ:SSII) meldete starke Finanzergebnisse f眉r das zweite Quartal 2025 mit einem rekordverd盲chtigen Quartalsumsatz von 10,0 Millionen US-Dollar, was einem Anstieg von 121,8 % gegen眉ber dem Vorjahr entspricht. Die Bruttomarge des Unternehmens stieg deutlich von 31,9 % auf 59,1 % im zweiten Quartal 2024, w盲hrend der Bruttogewinn um 311,4 % auf 5,9 Millionen US-Dollar zunahm.
Das chirurgische Robotersystem SSi Mantra verzeichnete im zweiten Quartal 23 neue Installationen, ein Anstieg von 130 % gegen眉ber dem Vorjahr, wodurch die Gesamtzahl der installierten Systeme auf 105 in sieben L盲ndern anstieg. Das Unternehmen meldete 4.657 kumulative Operationen und plant, bis September 2025 einen 510(k)-Antrag bei der FDA einzureichen. Zu den bemerkenswerten Erfolgen z盲hlen die weltweit erste robotergest眉tzte Herzoperation auf der westlichen Hemisph盲re sowie bahnbrechende Telesurgerieverfahren.
Das Unternehmen befindet sich in einer starken finanziellen Position mit keinen langfristigen Schulden und 11,4 Millionen US-Dollar in bar. SS Innovations wurde im April 2025 erfolgreich an der Nasdaq gelistet, was eine neue Phase in der globalen Expansionsstrategie markiert.
- Record quarterly revenue of $10.0 million, up 121.8% year-over-year
- Gross margin significantly expanded to 59.1% from 31.9% in Q2 2024
- SSi Mantra installations increased 130% to 23 units in Q2 2025
- Net loss narrowed substantially to $0.3 million from $4.1 million in Q2 2024
- Zero long-term debt with $11.4 million cash position
- Successful uplisting to Nasdaq in April 2025
- Achieved multiple 'world firsts' in robotic telesurgery and cardiac procedures
- Faster regulatory pathway through 510(k) application versus previous De Novo plan
- Company still operating at a net loss, though minimal
- Cash position of $11.4 million may require additional funding for global expansion
- Still awaiting key regulatory approvals in major markets (FDA and EU)
Insights
SS Innovations delivered exceptional Q2 results with 122% revenue growth and triple-digit margin expansion, nearing breakeven despite early commercialization stage.
SS Innovations has delivered a remarkable financial performance in Q2 2025 with
The most impressive aspect is the dramatic improvement in profitability metrics. Gross margin expanded significantly from
Revenue diversification is improving as well, with instrument sales growing
The financial position appears stable with
The company's plan to submit for FDA approval by September 2025 and potential EU certification by late 2025 outlines a clear path to major market expansion beyond their current footprint, which appears concentrated in India based on the surgical milestones mentioned.
Record Quarterly Revenue of
Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth 听听
FORT LAUDERDALE, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (the 鈥淐ompany鈥� or 鈥淪S Innovations鈥�) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2025.听听 The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission on August 6, 2025.
Second Quarter 2025 Overview
- Revenue increased
121.8% to$10.0 million from$4.5 million in the second quarter of 2024. - Gross margin expanded to
59.1% from31.9% in the second quarter of 2024. - Gross profit rose
311.4% to$5.9 million from$1.4 million in the second quarter of 2024. - Net loss of
$0.3 million , or$(0.00) per diluted share, compared to a net loss of$4.1 million , or$(0.02) per diluted share, in the second quarter of 2024. - SSi Mantra surgical robotic system installations totaled 23, up
130% from 10 installations in the second quarter of 2024 and up53% from 15 installations in the first quarter of 2025.
First Half 2025 Overview
- Revenue increased
85.6% to$15.1 million from$8.1 million in the first half of 2024. - Gross margin expanded to
46.3% from26.6% in the first half of 2024. - Gross profit rose
223.3% to$7.0 million from$2.2 million in the first half of 2024. - Net loss of
$5.9 million , or$(0.03) per diluted share, compared to net loss of$14.0 million , or$(0.08) per diluted share, in the first half of 2024. - SSi Mantra surgical robotic system installations totaled 38, up
100% from 19 installations in the first half of 2024.
As of June 30, 2025
- Long-term debt of
$0. - Cash and cash equivalents totaled
$11.4 million , excluding restricted cash.听听听 - SSi Mantra cumulative installed base totaled 105 in seven countries and cumulative surgeries reached 4,657.
CEO Commentary
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, 鈥淲e continue to execute on our strategic initiatives and delivered strong revenue growth in the second quarter of 2025, driven by higher unit sales of our advanced, cost-effective SSi Mantra 3 surgical robotic system in India and abroad. Our second quarter gross profit more than tripled compared to the prior year quarter, reflecting higher revenue and significant gross margin expansion due to lower production costs, propelling a sharp narrowing in net loss to almost breakeven.鈥澨�
Dr. Srivastava continued, 鈥淥ur SSi Mantra 3 surgical robotic system continues to pioneer robotic telesurgery and cardiac procedures, achieving several 鈥榳orld firsts鈥� during and after the second quarter. We remain committed to democratizing excellence in surgical robotic care and SS Innovations鈥� uplisting to Nasdaq in April 2025 symbolizes a new chapter of global expansion. In that regard, based on recent FDA conversations, we now expect to submit a 510(k) application for multiple indications for the SSi Mantra 3 to the U.S. Food and Drug Administration by the end of September 2025鈥攁 potentially quicker pathway compared to the De Novo application we previously planned. We also continue along the pathway towards a European Union CE marking certification as soon as late 2025. Looking to the second half of the year, an expanding installed base combined with growing utilization of the SSi Mantra 3 positions us well for continuing robust organic growth.鈥�
Select Business Highlights in Second Quarter 2025
- In April 2025, the Company鈥檚 common stock was listed for trading on The Nasdaq Stock Market LLC ("Nasdaq").
- In June 2025, the Company rang the opening bell at the Nasdaq MarketSite in New York City.
- In June 2025, the Company鈥檚 SSi Mantra surgical robotic system performed its first robotic cardiac surgery in the Western Hemisphere.
Subsequent Events
- In July 2025, the world鈥檚 first robotic telesurgery for weight loss was performed utilizing the Company鈥檚 SSi Mantra 3 surgical robotic system.
- In July 2025, the world鈥檚 first intercontinental robotic cardiac telesurgery was performed (from France to India) utilizing the Company鈥檚 SSi Mantra 3 surgical robotic system.
- In July 2025, the first telesurgery in India鈥檚 public sector, which consists of more than 25,000 public hospitals, was performed utilizing the Company鈥檚 SSi Mantra 3 surgical robotic system.
- As of July 31, 2025, the SSi Mantra cumulative installed base totaled 112 systems and cumulative multi-specialty surgeries reached 5,038 without any device-related adverse events. This total included 40 telesurgeries and 273 cardiac procedures.
Revenue Breakdown and Summary of Installations / Surgeries
| Category | Q2 2024 | Q2 2025 | Variance | Percentage | ||||
| System sales | $ | 4,258,198 | $ | 8,781,038 | $ | 4,522,840 | 106.2 | % |
| Instrument sales | 听 | 204,121 | 听 | 1,007,830 | 听 | 803,709 | 393.7 | % |
| Warranty sales | 听 | 28,795 | 听 | 193,359 | 听 | 164,564 | 571.5 | % |
| Lease income | 听 | 18,012 | 听 | 18,078 | 听 | 66 | 0.4 | % |
| Total revenue | $ | 4,509,126 | $ | 10,000,305 | $ | 5,491,179 | 121.8 | % |
| 听 | 听 | 听 | 听 | 听 | ||||
| SSi Mantra installations | 听 | 10 | 听 | 23 | 听 | 13 | 130 | % |
| Cumulative installed base1 | 听 | 37 | 听 | 105 | 听 | 68 | 184 | % |
| 听 | 听 | 听 | 听 | 听 | ||||
| SSi Mantra surgeries | 听 | 516 | 听 | 1,042 | 听 | 526 | 102 | % |
| Cumulative surgeries1 | 听 | 1,742 | 听 | 4,657 | 听 | 2,915 | 167 | % |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
1 at period end
| Category | H1 2024 | H1 2025 | Variance | Percentage | ||||
| System sales | $ | 7,752,957 | $ | 13,283,520 | $ | 5,530,563 | 71.3 | % |
| Instrument sales | 听 | 322,636 | 听 | 1,485,038 | 听 | 1,162,402 | 360.3 | % |
| Warranty sales | 听 | 38,202 | 听 | 315,863 | 听 | 277,661 | 726.8 | % |
| Lease income | 听 | 33,024 | 听 | 36,494 | 听 | 3,470 | 10.5 | % |
| Total revenue | $ | 8,146,819 | $ | 15,120,915 | $ | 6,974,096 | 85.6 | % |
| 听 | 听 | 听 | 听 | 听 | ||||
| SSi Mantra installations | 听 | 19 | 听 | 38 | 听 | 19 | 100 | % |
| SSi Mantra surgeries | 听 | 877 | 听 | 1,861 | 听 | 984 | 112 | % |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company鈥檚 product range includes its proprietary 鈥淪Si Mantra鈥� surgical robotic system and its comprehensive suite of 鈥淪Si Mudra鈥� surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company鈥檚 website at or for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渨ill,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渟eek,鈥� 鈥渄esigned,鈥� 鈥減otential,鈥� 鈥渇orecast,鈥� 鈥渢arget,鈥� 鈥渙bjective,鈥� 鈥済oal,鈥� or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations鈥� future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group听听听听听听听听
Kalle Ahl, CFA听听听听听听听听听听听听听听听听
T: (303) 953-9878听听听听听听听听
Devin Sullivan, Managing Director
T: (212) 836-9608
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
| SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | 听 | ||||||
| 听 | 听 | 听 | |||||
| 听 | As of | 听 | |||||
| 听 | June 30, 2025 | 听 | 听 | December 31, 2024 | |||
| ASSETS | 听 | 听 | 听 | 听 | 听 | ||
| Current Assets: | 听 | 听 | 听 | 听 | 听 | ||
| Cash and cash equivalents | $ | 11,375,265 | 听 | 听 | $ | 466,500 | 听 |
| Restricted cash | 听 | 5,884,513 | 听 | 听 | 听 | 5,838,508 | 听 |
| Accounts receivable, net | 听 | 5,973,923 | 听 | 听 | 听 | 4,466,047 | 听 |
| Inventory | 听 | 18,260,141 | 听 | 听 | 听 | 10,206,898 | 听 |
| Prepaids and other current assets | 听 | 9,292,684 | 听 | 听 | 听 | 6,438,338 | 听 |
| Total Current Assets | 听 | 50,786,526 | 听 | 听 | 听 | 27,416,291 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Property, plant, and equipment, net | 听 | 8,274,135 | 听 | 听 | 听 | 5,385,955 | 听 |
| Right of use asset, net | 听 | 2,654,775 | 听 | 听 | 听 | 2,623,880 | 听 |
| Deferred tax assets, net | 听 | 365,641 | 听 | 听 | 听 | - | 听 |
| Accounts receivable, net 鈥� non current | 听 | 4,447,389 | 听 | 听 | 听 | 3,299,032 | 听 |
| Restricted cash- non current | 听 | 345,900 | 听 | 听 | 听 | 318,527 | 听 |
| Prepaids and other non current assets | 听 | 3,103,405 | 听 | 听 | 听 | 3,341,528 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Total Assets | $ | 69,977,771 | 听 | 听 | $ | 42,385,213 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Current Liabilities | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Bank overdraft facility | $ | 6,980,313 | 听 | 听 | $ | 7,994,906 | 听 |
| Notes payable | 听 | - | 听 | 听 | 听 | 7,450,000 | 听 |
| Current portion of operating lease liabilities | 听 | 354,626 | 听 | 听 | 听 | 409,518 | 听 |
| Accounts payable | 听 | 6,079,794 | 听 | 听 | 听 | 2,312,382 | 听 |
| Deferred revenue | 听 | 2,412,682 | 听 | 听 | 听 | 1,278,602 | 听 |
| Accrued expenses & other current liabilities | 听 | 3,783,693 | 听 | 听 | 听 | 1,884,814 | 听 |
| Total Current Liabilities | 听 | 19,611,108 | 听 | 听 | 听 | 21,330,222 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Operating lease liabilities, less current portion | 听 | 2,452,389 | 听 | 听 | 听 | 2,349,118 | 听 |
| Deferred Revenue- non current | 听 | 5,779,525 | 听 | 听 | 听 | 5,173,953 | 听 |
| Other non current liabilities | 听 | 111,880 | 听 | 听 | 听 | 74,817 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Total Liabilities | $ | 27,954,902 | 听 | 听 | $ | 28,928,110 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Stockholders鈥� equity: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, | 听 | 1 | 听 | 听 | 听 | 1 | 听 |
| Common stock, 250,000,000 shares authorized, | 听 | 19,358 | 听 | 听 | 听 | 17,157 | 听 |
| Accumulated other comprehensive income (loss) | 听 | (822,813 | ) | 听 | 听 | (749,625 | ) |
| Additional paid in capital | 听 | 91,526,999 | 听 | 听 | 听 | 56,952,200 | 听 |
| Capital reserve | 听 | 899,917 | 听 | 听 | 听 | 899,917 | 听 |
| Accumulated deficit | 听 | (49,600,593 | ) | 听 | 听 | (43,662,547 | ) |
| Total stockholders鈥� equity | 听 | 42,022,869 | 听 | 听 | 听 | 13,457,103 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 69,977,771 | 听 | 听 | $ | 42,385,213 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | |||||||
| 听 | 听 | ||||||
| 听 | For The Three months ended | ||||||
| 听 | June 30, 2025 | 听 | June 30, 2024 | ||||
| 听 | 听 | 听 | 听 | ||||
| REVENUES | 听 | 听 | 听 | ||||
| System sales | 听 | 8,781,038 | 听 | 听 | 听 | 4,258,198 | 听 |
| Instruments sale | 听 | 1,007,830 | 听 | 听 | 听 | 204,121 | 听 |
| Warranty sale | 听 | 193,359 | 听 | 听 | 听 | 28,795 | 听 |
| Lease income | 听 | 18,078 | 听 | 听 | 听 | 18,012 | 听 |
| Total revenue | $ | 10,000,305 | 听 | 听 | $ | 4,509,126 | 听 |
| Cost of revenue | 听 | (4,085,247 | )听 | 听 | 听 | (3,071,340 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| GROSS PROFIT | 听 | 5,915,058 | 听 | 听 | 听 | 1,437,786 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| OPERATING EXPENSES: | 听 | 听 | 听 | 听 | 听 | ||
| Research & development expense | 听 | 498,600 | 听 | 听 | 听 | 759,004 | 听 |
| Stock compensation expense | 听 | 1,630,295 | 听 | 听 | 听 | 2,443,792 | 听 |
| Depreciation and amortization expense | 听 | 260,361 | 听 | 听 | 听 | 90,476 | 听 |
| Selling, general and administrative expense | 听 | 3,428,788 | 听 | 听 | 听 | 2,244,703 | 听 |
| TOTAL OPERATING EXPENSES | 听 | 5,818,044 | 听 | 听 | 听 | 5,537,975 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Income /(Loss) from operations | 听 | 97,014 | 听 | 听 | 听 | (4,100,189 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| OTHER INCOME (EXPENSE): | 听 | 听 | 听 | 听 | 听 | ||
| Interest Expense | 听 | (216,800 | )听 | 听 | 听 | (242,577 | )听 |
| Interest and other income, net | 听 | 216,824 | 听 | 听 | 听 | 202,196 | 听 |
| TOTAL INCOME / (EXPENSE), NET | 听 | 24 | 听 | 听 | 听 | (40,381 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| INCOME / (LOSS) BEFORE INCOME TAXES | 听 | 97,038 | 听 | 听 | 听 | (4,140,570 | )听 |
| Income tax expense | 听 | 353,729 | 听 | 听 | 听 | - | 听 |
| NET LOSS | $ | (256,691 | )听 | 听 | $ | (4,140,570 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Net loss per share -basic and diluted | $ | (0.00 | )听 | 听 | $ | (0.02 | )听 |
| Weighted average-basic shares | 听 | 193,571,635 | 听 | 听 | 听 | 170,739,380 | 听 |
| Weighted average-diluted shares | 听 | 202,835,698 | 听 | 听 | 听 | 181,843,313 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| NET LOSS | $ | (256,691 | )听 | 听 | $ | (4,140,570 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| OTHER COMPREHENSIVE INCOME (LOSS) | 听 | 听 | 听 | 听 | 听 | ||
| Foreign currency translation loss | 听 | (66,014 | )听 | 听 | 听 | (16,131 | )听 |
| Retirement Benefit (net of tax) | 听 | (35,660 | )听 | 听 | 听 | 3,299 | 听 |
| Income tax effect relating to retirement benefit | 听 | 5,772 | 听 | 听 | 听 | - | 听 |
| TOTAL OTHER COMPREHENSIVE INCOME (LOSS) | 听 | (95,902 | ) | 听 | 听 | (12,832 | ) |
| TOTAL COMPREHENSIVE LOSS | $ | (352,593 | )听 | 听 | $ | (4,153,402 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | |||||||
| 听 | 听 | ||||||
| 听 | For The Six months ended | ||||||
| 听 | June 30, 2025 | 听 | June 30, 2024 | ||||
| 听 | 听 | 听 | 听 | ||||
| REVENUES | 听 | 听 | 听 | ||||
| System sales | 听 | 13,283,520 | 听 | 听 | 听 | 7,752,957 | 听 |
| Instruments sale | 听 | 1,485,038 | 听 | 听 | 听 | 322,636 | 听 |
| Warranty sale | 听 | 315,863 | 听 | 听 | 听 | 38,202 | 听 |
| Lease income | 听 | 36,494 | 听 | 听 | 听 | 33,024 | 听 |
| Total revenue | $ | 15,120,915 | 听 | 听 | $ | 8,146,819 | 听 |
| Cost of revenue | 听 | (8,118,649 | )听 | 听 | 听 | (5,980,851 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| GROSS PROFIT | 听 | 7,002,266 | 听 | 听 | 听 | 2,165,968 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| OPERATING EXPENSES: | 听 | 听 | 听 | 听 | 听 | ||
| Research & development expense | 听 | 1,508,695 | 听 | 听 | 听 | 1,286,995 | 听 |
| Stock compensation expense | 听 | 4,009,507 | 听 | 听 | 听 | 9,552,542 | 听 |
| Depreciation and amortization expense | 听 | 469,243 | 听 | 听 | 听 | 170,577 | 听 |
| Selling, general and administrative expense | 听 | 6,638,587 | 听 | 听 | 听 | 5,088,362 | 听 |
| TOTAL OPERATING EXPENSES | 听 | 12,626,032 | 听 | 听 | 听 | 16,098,476 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Loss from operations | 听 | (5,623,766 | )听 | 听 | 听 | (13,932,508 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| OTHER INCOME (EXPENSE): | 听 | 听 | 听 | 听 | 听 | ||
| Interest Expense | 听 | (596,705 | )听 | 听 | 听 | (432,665 | )听 |
| Interest and other income, net | 听 | 636,156 | 听 | 听 | 听 | 382,850 | 听 |
| TOTAL INCOME / (EXPENSE), NET | 听 | 39,451 | 听 | 听 | 听 | (49,815 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| LOSS BEFORE INCOME TAXES | 听 | (5,584,315 | )听 | 听 | 听 | (13,982,323 | )听 |
| Income tax expense | 听 | 353,729 | 听 | 听 | 听 | - | 听 |
| NET LOSS | $ | (5,938,044 | )听 | 听 | $ | (13,982,323 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Net loss per share - basic and diluted | $ | (0.03 | )听 | 听 | $ | (0.08 | )听 |
| Weighted average- basic shares | 听 | 186,244,872 | 听 | 听 | 听 | 170,734,435 | 听 |
| Weighted average- diluted shares | 听 | 195,502,268 | 听 | 听 | 听 | 181,726,502 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| NET LOSS | $ | (5,938,044 | )听 | 听 | $ | (13,982,323 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| OTHER COMPREHENSIVE INCOME (LOSS) | 听 | 听 | 听 | 听 | 听 | ||
| Foreign currency translation loss | 听 | (59,138 | )听 | 听 | 听 | (95,445 | )听 |
| Retirement Benefit (net of tax) | 听 | (19,822 | )听 | 听 | 听 | 11,806 | 听 |
| Income tax effect relating to retirement benefit | 听 | 5,772 | 听 | 听 | 听 | - | 听 |
| TOTAL OTHER COMPREHENSIVE INCOME (LOSS) | 听 | (73,188 | ) | 听 | 听 | (83,639 | ) |
| TOTAL COMPREHENSIVE LOSS | $ | (6,011,232 | )听 | 听 | $ | (14,065,962 | )听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| SS INNOVATIONS INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||
| 听 | 听 | 听 | 听 | |||||
| 听 | 听 | For the Six months ended | 听 | |||||
| 听 | 听 | June 30, 2025 | 听 | 听 | June 30, 2024 | 听 | ||
| Cash flows from operating activities: | 听 | 听 | 听 | 听 | 听 | 听 | ||
| Net loss | 听 | $ | (5,938,044 | ) | 听 | $ | (13,982,323 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Depreciation and amortization | 听 | 听 | 469,243 | 听 | 听 | 听 | 170,577 | 听 |
| Operating lease expense | 听 | 听 | 423,593 | 听 | 听 | 听 | 357,533 | 听 |
| Interest Expense | 听 | 听 | 179,455 | 听 | 听 | 听 | 182,530 | 听 |
| Interest and other income, net | 听 | 听 | (338,191 | ) | 听 | 听 | (175,147 | ) |
| (Reversal of) / Provision for credit loss reserve | 听 | 听 | (228,846 | ) | 听 | 听 | 573,048 | 听 |
| Deferred income tax benefit | 听 | 听 | (365,641 | ) | 听 | 听 | - | 听 |
| Stock compensation expense | 听 | 听 | 4,009,507 | 听 | 听 | 听 | 9,552,542 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Changes in operating assets and liabilities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Accounts receivable, net | 听 | 听 | (2,337,679 | ) | 听 | 听 | (3,475,878 | ) |
| Inventory, net | 听 | 听 | (10,221,214 | ) | 听 | 听 | (199,750 | ) |
| Deferred revenue | 听 | 听 | 1,739,652 | 听 | 听 | 听 | 3,032,484 | 听 |
| Prepaids and other assets | 听 | 听 | (2,572,481 | ) | 听 | 听 | (421,539 | ) |
| Accounts payable | 听 | 听 | 3,782,409 | 听 | 听 | 听 | 224,821 | 听 |
| Income taxes payable, net | 听 | 听 | 620,586 | 听 | 听 | 听 | - | 听 |
| Accrued expenses & other liabilities | 听 | 听 | 1,629,136 | 听 | 听 | 听 | 808,818 | 听 |
| Operating lease payment | 听 | 听 | (407,188 | ) | 听 | 听 | (342,202 | ) |
| Net cash used in operating activities | 听 | 听 | (9,555,703 | ) | 听 | 听 | (3,694,486 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Cash flows from investing activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Purchase of property, plant and equipment | 听 | 听 | (1,189,452 | ) | 听 | 听 | (2,239,139 | ) |
| Net cash used in investing activities | 听 | 听 | (1,189,452 | ) | 听 | 听 | (2,239,139 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Cash flows from financing activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Proceeds from bank overdraft facility (net) | 听 | 听 | (1,014,593 | ) | 听 | 听 | 842,610 | 听 |
| Proceeds from issuance of convertible notes to principal shareholder | 听 | 听 | 28,000,000 | 听 | 听 | 听 | 3,000,000 | 听 |
| Proceeds from issuance of convertible notes to other investors | 听 | 听 | - | 听 | 听 | 听 | 1,450,000 | 听 |
| Repayment of convertible notes to principal shareholder, including interest | 听 | 听 | (4,212,637 | ) | 听 | 听 | - | 听 |
| Repayment of convertible notes to other investors, including interest | 听 | 听 | (1,068,849 | ) | 听 | 听 | - | 听 |
| Net cash provided by financing activities | 听 | 听 | 21,703,921 | 听 | 听 | 听 | 5,292,610 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Net change in cash | 听 | 听 | 10,958,766 | 听 | 听 | 听 | (641,015 | ) |
| Effect of exchange rate on cash | 听 | 听 | 23,377 | 听 | 听 | 听 | 108,572 | 听 |
| Cash and cash equivalents at the beginning of the period | 听 | 听 | 6,623,535 | 听 | 听 | 听 | 7,087,845 | 听 |
| Cash and cash equivalents at end of the period | 听 | $ | 17,605,678 | 听 | 听 | $ | 6,555,402 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Supplemental disclosure of cash flow information: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Conversion of convertible notes into common stock, including interest | 听 | $ | 30,645,360 | 听 | 听 | $ | - | 听 |
| Transfer of systems from inventory to property, plant and equipment | 听 | $ | 2,167,971 | 听 | 听 | $ | 1,422,880 | 听 |
FAQ
What were SS Innovations (SSII) Q2 2025 earnings results?
How many SSi Mantra surgical robots were installed in Q2 2025?
What is SS Innovations' (SSII) regulatory timeline for FDA approval?
How many surgeries have been performed with SS Innovations' robotic system?
What is SS Innovations' (SSII) current financial position?
